SD-169 是一种可口服的 ATP 竞争性MAPK p38α抑制剂，IC50值为 3.2 nM。它对p38β MAPK的IC50值为 122 nM。它通过抑制 T 细胞的浸润和活化阻止糖尿病的发展。

SD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.

Animals were gavaged with Scios SD-169 (10 or 30 mg/kg) or excipient (PEG300) 1 day before and daily after crush injury to the sciatic nerve.?SD-169 is a proprietary oral inhibitor of p38 MAPK activity.?The rate of axonal regeneration was determined by the functional pinch test and was significantly increased in treated animals 8 days after crush injury (P< 0.05;?30 mg/kg dose).?In SD-169-treated animals with nerve transection, nerve fibers regenerating through a silicone chamber were morphologically more mature than untreated nerves when observed 28 days after transection.?TNF immunofluorescence of distal nerve segments after crush injury suggested that SD-169 reduced SC TNF protein[1].

1670-87-7

C9H8N2O

160.176

SD 169;1H-吲哚-5-甲酰胺

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years